Skip to Content

Ziagen (abacavir)

Audience: Infectious Disease and other healthcare professionals

GlaxoSmithKline (GSK) notified healthcare professionals of a high rate of early virologic non-response observed in a GSK-sponsored clinical study of therapy-naive adults with HIV infection receiving once-daily three-drug combination therapy with lamivudine (Epivir, GSK), abacavir (Ziagen, GSK) and tenofovir (Viread, TDF, Gilead Sciences). Based on these results: Abacavir and lamivudine in combination with tenofovir should not be used as a triple antiretroviral therapy when considering a new treatment regimen for naive or pre-treated patients.

[July, 2003 Letter - GlaxoSmithKline] PDF Format